PMID- 25034590
OWN - NLM
STAT- MEDLINE
DCOM- 20150716
LR  - 20230926
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 17
IP  - 7
DP  - 2014 Jul 20
TI  - [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
PG  - 575-80
LID - 10.3779/j.issn.1009-3419.2014.07.14 [doi]
AB  - Lung cancer is the leading cause of death from cancer in the world. The treatment 
      remains one of the most challenging tasks in the medical world. The discovery and 
      development of epidermal growth factor receptor-tyrosine kinase inhibitor 
      (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer 
      (NSCLC). But the efficacy of EGFR-TKI in EGFR wild-type patients is limited, and 
      the limited EGFR mutation incidence also prompts researchers to study what is the 
      best treatment choice for patients with NSCLC who are negative for EGFR 
      mutations. This review will discuss the research status in treatment choice for 
      EGFR wild-type NSCLC.
FAU - Ma, Feng
AU  - Ma F
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - Shi, Xiaoyu
AU  - Shi X
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - Meng, Wei
AU  - Meng W
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - Zhao, Lixia
AU  - Zhao L
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - He, Xiaohua
AU  - He X
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
FAU - Zhao, Junfeng
AU  - Zhao J
AD  - Department of Medical Oncology, the First Affiliated Hospital of Hebei North 
      University, Zhangjiakou 075000, China.
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics
MH  - Protein Kinase Inhibitors/*therapeutic use
PMC - PMC6000467
EDAT- 2014/07/19 06:00
MHDA- 2015/07/17 06:00
PMCR- 2014/07/20
CRDT- 2014/07/19 06:00
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2015/07/17 06:00 [medline]
PHST- 2014/07/20 00:00 [pmc-release]
AID - zgfazz-17-7-575 [pii]
AID - 10.3779/j.issn.1009-3419.2014.07.14 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2014 Jul 20;17(7):575-80. doi: 
      10.3779/j.issn.1009-3419.2014.07.14.